Latest Articles
Heranova: Detecting endometriosis in the blood like it’s cancer - BioCentury
Heranova: Detecting endometriosis in the blood like it’s cancer BioCentury
Published: March 27, 2025, 11:13 p.m.
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - StockTitan
Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer StockTitan
Published: March 27, 2025, 9:44 p.m.
Dr Eskander on the Potential Clinical Benefit of Nivolumab in dMMR Endometrial Cancer - OncLive
Dr Eskander on the Potential Clinical Benefit of Nivolumab in dMMR Endometrial Cancer OncLive
Published: March 27, 2025, 9:23 p.m.
Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld Online
Acrivon narrows focus for ACR-368 in endometrial cancer BioWorld Online
Published: March 27, 2025, 3 p.m.
EDAP Shatters Records: 51% US Growth as HIFU Technology Transforms Cancer Treatment - StockTitan
EDAP Shatters Records: 51% US Growth as HIFU Technology Transforms Cancer Treatment StockTitan
Published: March 27, 2025, 11:10 a.m.
Endometrial cancer patients to receive funded immunotherapy - Hong Kong Standard
Endometrial cancer patients to receive funded immunotherapy Hong Kong Standard
Published: March 27, 2025, 9:09 a.m.
SIRT7 facilitates endometrial cancer progression by regulating PTEN stability in an estrogen-dependent manner - Nature.com
SIRT7 facilitates endometrial cancer progression by regulating PTEN stability in an estrogen-dependent manner Nature.com
Published: March 27, 2025, 6:35 a.m.
Transcription factor addictions: exploring the potential Achilles' Heel of endometriosis.
A considerable number of women of reproductive age suffer from endometriosis worldwide. There is a significant physical, mental, and financial burden on patients affected by this condition in terms of …
Published: March 27, 2025, midnight
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer - OncLive
Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer OncLive
Published: March 26, 2025, 10:21 p.m.
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer Endpoints News
Published: March 26, 2025, 2:10 p.m.
Link copied to clipboard!